Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Circulating tumor DNA (ctDNA) is fragmented DNA from tumors found in the bloodstream.
• Liquid biopsy is a minimally invasive technique to analyze ctDNA for cancer-specific abnormalities.
• ctDNA analysis represents a paradigm shift in cancer diagnostics and management.

Purpose of the Study:

• To review the current evidence on ctDNA applications in diagnosing and managing gastrointestinal (GI) tumors.
• To highlight ctDNA's role in early detection, risk stratification, and therapy guidance for GI cancers.
• To emphasize ctDNA's potential in reducing the global burden of GI malignancies.

Main Methods:

• Review of current scientific literature on ctDNA and liquid biopsy technologies.
• Analysis of ctDNA's utility in detecting minimal residual disease and tumor heterogeneity.
• Evaluation of ctDNA as a surrogate marker for treatment response and survival outcomes.

Main Results:

• Liquid biopsies enable early disease detection, improved risk stratification, and capture of tumor evolution.
• ctDNA monitoring guides adjuvant and palliative cancer therapy, including neoadjuvant and postoperative treatment.
• ctDNA clearance is being researched as an endpoint for chemotherapy escalation/de-escalation in high-risk patients.

Conclusions:

• ctDNA technology is a powerful tool for the diagnosis and management of GI cancers.
• Liquid biopsy offers a minimally invasive approach with significant potential to impact patient outcomes.
• Further research into ctDNA as a surrogate for survival endpoints can expedite new therapy development.